Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Up and down and up and down and up and down

<< Previous

Bullboard Posts

Next >>

Post by ScienceFirston Apr 17, 2023 4:44pm

395 Views

Post# 35399188

Up and down and up and down and up and down

Looking at the 1y chart, the share price has been manipulated, so many times. The current pullback is not even surprizing.

With the upcoming events (AUA, new data, etc ...), I expect it to rebound. Even if BDT would be pushed a little bit for justified reasons. That might mean that they're awaiting even more robust efficacy % and want them to be included in a data output. Note that, if IRBX treatment (N-803 + BCG) is approved at 1y date (May 23, 2023), it would indeed be wise to delay a bit to include more data displaying higher efficacy data, just to be on the more convincing side.

https://www.urologytimes.com/view/fda-accepts-application-for-n-803-in-nmibc

IRBX results from the study presented at the 2022 AUA Annual Meeting showed that at a median follow-up of 23.9 months in patients with CIS, the complete response (CR) rate was 71% (95% CI, 60.1%-80.5%).2 The 12- and 24-month CR rates were 60% (95% CI, 45%-72%) and 52% (95% CI, 40%-65%), respectively.

Under the Prescription Drug User Fee Act, the target action date for the IRBX's BLA is May 23, 2023.

All patients treated in the IRBX study will receive via a urinary catheter in the bladder, BCG plus N-803 or N-803 only weekly for 6 consecutive weeks (initial induction treatment period). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.

Swings over the last year on TLT's stock:

Up and down and up and down and up and down and up and down ...

May 25 ... 0.30$

June 1st ... 0.425$ (so +42%)

June 13 ... 0.29$ (so -30%)

July 26 ...0.275$

Aug. 3 ... 0.36$ (so +31%)

Aug. 22 ... 0.37$

Sept. 8 ... 0.245$ (so -34%)

Nov. 16 ... 0.245$ (ahead of p#25 data @450-days)

Nov. 28 ... 0.33$ (so +35%)

Jan. 3rd ... 0.33$ (day of the BioTuesday article)